Atlanta-Results of a Medicare claims analysis of women undergoing a sling procedure for stress urinary incontinence have revealed a significant variation between gynecologists and urologists in their approach to patient evaluation and the outcomes after surgery. However, further study is needed to understand the factors underlying those differences, researchers from UCLA said at the AUA annual meeting here.
Atlanta-As radiofrequency ablation emerges as a minimally invasive treatment option for small-cell renal carcinoma, urologists should consider including biopsy as a normal component of patient follow-up, say researchers from the Cleveland Clinic.
Atlanta-Several groups have recently demonstrated the safety and efficacy of radiofrequency ablation in select patients ineligible for surgical excision of small renal tumors. Short-term data from these single-institution studies were presented at the AUA annual meeting here.
Endopelvic fascia and dorsal venous complex are left intact, one of the hallmarks of this technique.
Atlanta-An investigational vaccine directed against prostate cancer cells has been found to be well tolerated with minimal toxicity in patients with hormone-refractory prostate cancer. In patients receiving the agent, median survival appeared to be enhanced when compared with accepted nomograms, reported researchers from Virginia Mason Medical Center, Seattle. These results were from two phase II trials of the vaccine, known as GVAX, presented at the AUA annual meeting here.
Atlanta-Combining the endothelin A (ETA) receptor antagonist atrasentan (Xinlay) with taxane chemotherapy has a significant additive effect against prostate cancer, results of a preclinical investigation presented at the AUA annual meeting here have demonstrated.
Atlanta-The decision about when to intervene in patients with small, low-grade prostate tumors can be a tough one for both patient and physician. A study from The Johns Hopkins Hospital, Baltimore, suggests that these men may have 2 years or longer to make a decision without compromising effective treatment.
Atlanta-Laurence H. Klotz, MD, looks momentarily at the data generated by his study of the role that PSA kinetics might play in influencing intervention in men with low-risk prostate cancer and summarizes the findings in a single observation: "It is hard to argue with 99% disease-specific survival."
Atlanta-Phosphodiesterase-5 inhibitor therapy, which is commonly used to treat erectile dysfunction, may have a paradoxical benefit as a treatment for priapism in patients with sickle cell anemia, according to research presented at the AUA annual meeting here and at the American Society of Andrology annual meeting in Chicago.
Atlanta-Which procedure nets better results for patients with Peyronie's disease-corporeal plication or plaque incision with venous grafting? According to a long-term study from Kaiser Permanente Medical Center in Los Angeles, there is no difference between the two procedures in terms of patient satisfaction. The major difference between the two is time spent in the operating room.
Atlanta-Surgeons from Italy have developed a technique to take tissue from the underside of the tongue and transplant it to repair strictures in the urethra, giving surgeons an alternative to buccal mucosa for the procedure.
Atlanta-Remission of erectile dysfunction may be more common than has been previously believed, according to an analysis of data from the National Institutes of Health-supported Massachusetts Male Aging Study (MMAS). Findings from this analysis were reported at the AUA annual meeting here.
When we replace testosterone, we bring the serum testosterone levels in hormone-deficient men to that of their eugonadal peers.
Atlanta-Testosterone replacement therapy (TRT) caused no adverse events in the prostate tissue of men with androgen decline of aging male (ADAM) syndrome after 6 months of treatment, according to a study presented at the AUA annual meeting here.
AUA president Lawrence S. Ross, MD, discusses current issues related to training, as well as the urology work force and maintenance of certification.
Atlanta-Despite recent medical advances, no consensus exists about the optimal treatment for patients with localized prostate cancer, members of an AUA clinical guideline panel have concluded.
For the two to four million American men who suffer from hypogonadism or "andropause," is treatment with androgen replacement therapy safe, particularly in older men?
The University of Texas M.D. Anderson Cancer Center, Houston, has started treating patients at its Proton Therapy Center, the first facility associated with a comprehensive cancer center and the fourth such facility in the United States.
Peter Scardino, MD, has been named the new chairman of the department of surgery at Memorial Sloan-Kettering Cancer Center, New York.
An oral drug under development for the treatment of multiple side effects of androgen deprivation therapy appears to lower total cholesterol levels, according to an interim analysis of phase III clinical trial results.
An external or "condom" catheter appears to reduce the risk of urinary tract infections or death by 80 percent compared with an indwelling catheter, according to a randomized, controlled trial comparing the two types of catheters.
The second of two phase III trials has shown that once-daily trospium chloride (Sanctura XR) reduces frequency of urination and the number of urge incontinence episodes in individuals with a once-daily formulation for the treatment of overactive bladder.
Men who receive radiation therapy for prostate cancer are not at any appreciable increased risk of developing rectal cancer compared with those not given radiation therapy, according to a recently published study by Canadian researchers.
Prostate cancer patients make treatment decisions that are influenced by anecdote and misconception rather than clinical trial evidence, according to a study by researchers at the University of Colorado Health Sciences Center, Denver.
Medical Faculty Associates at the George Washington University has named Thomas Jarrett, MD, as the new chair of its department of urology.
Among patients with locally advanced or metastatic prostate cancer, the decision about whether to receive androgen deprivation therapy depends primarily on who their urologist is, rather than the stage or grade of tumor or patient characteristics.
Teva Pharmaceutical Industries Ltd. has received final FDA approval to market a generic formulation of finasteride tablets, 5 mg.
A new prognostic test may help determine whether a patient with prostate cancer will have a recurrence of the disease, even if surrounding lymph nodes initially appear negative for cancer, according to a study from the Keck School of Medicine at the University of Southern California, Los Angeles.
Prostate cancer patients make treatment decisions that are influenced by anecdote and misconception rather than clinical trial evidence, according to a study by researchers at the University of Colorado Health Sciences Center, Denver.
Moderately and severely obese prostate cancer patients had a 99% greater risk of developing biochemical failure than other patients, according to the authors of a study from the University of Texas M.D. Anderson Cancer Center, Houston.
